AMA 2017: New president urges physicians to rise above ‘hyper-partisan political climate’

In his first address as president of the American Medical Association, David Barbe, MD, MHA, encouraged physicians at the AMA’s annual meeting in Chicago to “put their expertise to work” in the debate over healthcare legislation and not be “corrupted or co-opted” by partisanship.

Barbe repeatedly asked the AMA crowd “What kind of leaders will we be?” For examples of what not to do, he pointed to Congress, where the Affordable Care Act (ACA) was passed entirely by one political party and may now be repealed only by its opponents, and as Barbe described it, factions have been saying “hell no” to working together.

“I submit to you: that might be good theater, but it is not good policy, it’s not good politics and it is definitely not good leadership,” he said. “Good leadership is constructive, consensus-building and principled. Yet, good leadership lays down few absolutes.”

One of those few absolutes, he added, is that no one who gained coverage thanks to the ACA should lose it. Achieving that goal, however, doesn’t mean the AMA should be inflexible, and he expressed an openness to alternative approaches and more cost-effective ways to cover the uninsured.

He said physicians should use their experience with “difficult conversations” to work with both Republicans and Democrats.

“Our role in today’s advocacy climate means de-escalating highly charged partisan rhetoric,” he said. “It means working with all stakeholders on issues that are simply too big to be left to the parochial interests of one party or the other. When it comes to health care advocacy, we are the leaders.”

Barbe’s speech was far from the only conversation at the AMA meeting about the ACA and its Republican-sponsored replacement, the American Health Care Act (AHCA). It was also the focus of the speech from his predecessor, Andrew Gurman, MD, and senior vice president for advocacy Richard Deem gave an update on the AMA’s efforts to change the House-passed version of the AHCA.

 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.